Industry and Academia Collaborate for Lupus

The global pharmaceutical company Merck Serono is collaborating with a leading academic center, the Feinstein Institute, to “develop antibodies for the treatment of systemic lupus erythematosus (SLE). Under the terms of the agreement, Merck Serono will fund a research program at the Feinstein Institute and be responsible for the development and commercialization of the antibodies resulting from the collaboration.”

Margaret Dowd, President and CEO of the LRI applauds the two organizations for combining their resources to benefit lupus patients. Referring to a current research partnership between the LRI and the U.S. subsidiary of Merck Serono, Ms. Dowd comments, “Collaborating with industry leaders like EMD Serono is helping us drive lupus research to the next level — from science to solutions, from innovation to impact,” said Margaret Dowd, LRI President and CEO. “Industry partnerships offer a new approach to funding the best novel research that can speed progress to new drug development for people with lupus.”

Full Story